VENATORX PHARMACEUTICALS, INC MALVERN, PA, USA
ORAL PBPi to treat multi-drug-resistant gonorrhea
Direct-Acting Small Molecule Therapeutic
Drug-resistant bacteria is a growing urgent global health and health security threat, exacerbated by limited diagnostics and treatment options. Venatorx is developing an oral cyclic-boronate penicillin-binding proteins (PBP) inhibitor for 3rd-generation-cephalosporin (3GC)-resistant gonorrhea as a last-resort treatment against the most resistant strains of the Neisseria gonorrhoeae superbug. Venatorx is developing an oral penicillin-binding protein inhibitor (PBPi) to address the growing problem of resistance in Neisseria gonorrhoeae to the last resort antibiotic for outpatient use, ceftriaxone. Venatorx has identified non-beta-lactam transpeptidase inhibitors that are rapidly bactericidal, impervious to beta-lactamases, and show promising selective activity against gonococci, including both wild-type strains and isolates with PBP variants that confer ceftriaxone resistance. CARB-X funding will help Venatorx progress these early molecules from hit-to-lead through IND-enabling studies.
Current Development Stage: Hit-to-lead
CARB-X Investment: Initial investment of up to $4.1m with potential option payments up to $8.9m.
Initial CARB-X Investment Date: September 1, 2019